Healthcare provider profile · identity verified

Lorelei Darlene Tan, MD

Family Practice · MARTINEZ, CA · NPI 1508914532

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	375	165
Simvastatin	Simvastatin	227	86
Lisinopril	Lisinopril	217	85
Levothyroxine Sodium	Levothyroxine Sodium	183	71
Losartan Potassium	Losartan Potassium	167	78
Amlodipine Besylate	Amlodipine Besylate	147	71
Hydrochlorothiazide	Hydrochlorothiazide	134	56
Atenolol	Atenolol	133	59
Albuterol Sulfate Hfa	Albuterol Sulfate	121	84
Metoprolol Tartrate	Metoprolol Tartrate	121	51
Metformin Hcl Er	Metformin Hcl	119	54
Gabapentin	Gabapentin	97	43
Alvesco	Ciclesonide	96	29
Hydralazine Hcl	Hydralazine Hcl	73	22
Alendronate Sodium	Alendronate Sodium	72	32
Trazodone Hcl	Trazodone Hcl	72	28
Allopurinol	Allopurinol	69	34
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	69	24
Pantoprazole Sodium	Pantoprazole Sodium	69	30
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	63	28
Glipizide	Glipizide	60	24
Nabumetone	Nabumetone	56	33
Famotidine	Famotidine	52	29
Tamsulosin Hcl	Tamsulosin Hcl	52	25
Metformin Hcl	Metformin Hcl	51	26
Terazosin Hcl	Terazosin Hcl	49	18
Temazepam	Temazepam	46	13
Tizanidine Hcl	Tizanidine Hcl	45	22
Lovastatin	Lovastatin	44	18
Furosemide	Furosemide	41	21
Potassium Chloride	Potassium Chloride	39	16
Carvedilol	Carvedilol	38	17
Sertraline Hcl	Sertraline Hcl	38	12
Citalopram Hbr	Citalopram Hydrobromide	37	17
Prednisone	Prednisone	37	31
Baclofen	Baclofen	36	26
Duloxetine Hcl	Duloxetine Hcl	36	14
Montelukast Sodium	Montelukast Sodium	36	12
Triamcinolone Acetonide	Triamcinolone Acetonide	36	25
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	32	suppressed
Cephalexin	Cephalexin	30	23
Humulin N	Insulin Nph Human Isophane	29	12
Sumatriptan Succinate	Sumatriptan Succinate	28	11
Spiriva Respimat	Tiotropium Bromide	26	13
Wixela Inhub	Fluticasone Propion/Salmeterol	26	suppressed
Amoxicillin	Amoxicillin	24	12
Hydrocortisone	Hydrocortisone	24	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	24	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	23	23
Nystatin	Nystatin	23	suppressed
Pravastatin Sodium	Pravastatin Sodium	23	12
Acyclovir	Acyclovir	22	13
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	22	22
Metoprolol Succinate	Metoprolol Succinate	22	11
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	21
Ibuprofen	Ibuprofen	21	17
Paxlovid	Nirmatrelvir/Ritonavir	21	21
Rosuvastatin Calcium	Rosuvastatin Calcium	21	12
Fluocinonide	Fluocinonide	20	13
Fluoxetine Hcl	Fluoxetine Hcl	20	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	20	suppressed
Fluticasone Propionate	Fluticasone Propionate	19	18
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Omeprazole	Omeprazole	18	11
Levofloxacin	Levofloxacin	17	17
Warfarin Sodium	Warfarin Sodium	17	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	16	12
Azithromycin	Azithromycin	15	15
Spironolactone	Spironolactone	15	suppressed
Bupropion Hcl Sr	Bupropion Hcl	14	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Lorazepam	Lorazepam	13	12
Meloxicam	Meloxicam	13	11
Metronidazole	Metronidazole	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Fenofibrate	Fenofibrate	12	suppressed
Finasteride	Finasteride	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Veo Insulin Syringe	Syrge-Ndl,ins 0.3 Ml Half Mark	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error